MCID: UTR024
MIFTS: 58

Uterine Carcinosarcoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Uterine Carcinosarcoma

MalaCards integrated aliases for Uterine Carcinosarcoma:

Name: Uterine Carcinosarcoma 11 19 58 53 5 14 16 71
Carcinosarcoma of the Corpus Uteri 19 58
Malignant Mixed Müllerian Tumor of the Corpus Uteri 19
Malignant Mixed Mullerian Tumor of the Corpus Uteri 58
Malignant Mixed Müllerian Tumor of Corpus Uteri 19
Mixed Müllerian Cancer of Corpus Uteri 19
Mixed Mullerian Cancer of Corpus Uteri 58
Mixed Mullerian Sarcoma of Uterus 11
Uterine Corpus Carcinosarcoma 71

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 11 DOID:6171
NCIt 49 C42700
SNOMED-CT 68 702369008
ICD10 via Orphanet 32 C54.9
Orphanet 58 ORPHA213610
UMLS 71 C0280630 C1704376

Summaries for Uterine Carcinosarcoma

GARD: 19 Carcinosarcoma of the corpus uteri is a rare, malignant, mixed epithelial and mesenchymal tumor of the uterine body composed of high-grade carcinomatous and sarcomatous elements. It may present with vaginal bleeding, abnormal vaginal discharge, abdominal pain and/or pelvic mass, with a polypoid tumor sometimes protruding through the cervical canal. Association with Tamoxifen therapy, long-term unopposed estrogen use and previous pelvic radiotherapy has been reported.

MalaCards based summary: Uterine Carcinosarcoma, also known as carcinosarcoma of the corpus uteri, is related to carcinosarcoma and sarcoma, and has symptoms including pelvic pain An important gene associated with Uterine Carcinosarcoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Decreased viability

Orphanet: 58 Carcinosarcoma of the corpus uteri is a rare, malignant, mixed epithelial and mesenchymal tumor of the uterine body composed of high-grade carcinomatous and sarcomatous elements. It may present with vaginal bleeding, abnormal vaginal discharge, abdominal pain and/or pelvic mass, with a polypoid tumor sometimes protruding through the cervical canal. Association with Tamoxifen therapy, long-term unopposed estrogen use and previous pelvic radiotherapy has been reported.

Disease Ontology: 11 A uterine body mixed cancer that has material basis in both endometrial carcinoma and sarcoma.

Related Diseases for Uterine Carcinosarcoma

Diseases related to Uterine Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 442)
# Related Disease Score Top Affiliating Genes
1 carcinosarcoma 31.6 VIM TP53 PTEN PPP2R1A PIK3CA KIT
2 sarcoma 31.2 VIM TP53 PIK3CA KIT HRAS
3 adenomyosis 30.8 TP53 PTGS2 PTEN
4 endometrial stromal sarcoma 30.8 VIM TP53 KIT H2AC18
5 serous cystadenocarcinoma 30.6 TP53 PTEN PPP2R1A POLE PIK3CA HRAS
6 endometrial cancer 30.5 TP53 PTGS2 PTEN PIK3R1 PIK3CA KIT
7 inherited cancer-predisposing syndrome 30.5 TP53 PTEN POLE KIT EGFR
8 bap1 tumor predisposition syndrome 30.5 TP53 PTEN POLE KIT EGFR
9 endometrial adenocarcinoma 30.4 TP53 PTEN POLE FGFR2 EGFR
10 fallopian tube carcinoma 30.4 TP53 PTEN ERBB2
11 endometrial serous adenocarcinoma 30.4 TP53 PTEN PPP2R1A POLE PIK3CA FBXW7
12 papillary serous adenocarcinoma 30.4 TP53 HRAS ERBB2
13 spindle cell sarcoma 30.4 VIM TP53 KIT
14 rhabdomyosarcoma 30.4 VIM TP53 PTEN PIK3CA LRRC56 KIT
15 large cell neuroendocrine carcinoma 30.4 TP53 HRAS EGFR
16 adenosarcoma 30.4 VIM TP53 KIT ERBB2
17 adenocarcinoma 30.4 TP53 PTGS2 PTEN PIK3CA HRAS FGFR2
18 myoma 30.3 TP53 KIT EGFR
19 chordoma 30.3 VIM TP53 PTEN EGFR
20 angiosarcoma 30.3 VIM KRT8 KIT
21 cervical squamous cell carcinoma 30.2 TP53 PTEN PIK3CA KRT8 FBXW7 EGFR
22 colon adenocarcinoma 30.1 TP53 PTGS2 PIK3CA HRAS FBXW7 EGFR
23 mixed cell type cancer 30.1 TP53 PTEN PPP2R1A POLE PIK3CA KIT
24 myelodysplastic syndrome 29.9 U2AF1 TP53 LRRC56 KIT HRAS H2AC18
25 wilms tumor 1 29.9 U2AF1 TP53 PTEN KIT HRAS H2AC18
26 peripheral nervous system disease 29.8 U2AF1 TP53 PTGS2 PTEN KIT HRAS
27 colonic benign neoplasm 29.7 TP53 PTGS2 PTEN PIK3CA HRAS H2AC18
28 lynch syndrome 29.7 U2AF1 TP53 PTGS2 PTEN PPP2R1A POLE
29 cervical cancer 29.7 U2AF1 TP53 PTGS2 PTEN PIK3CA LRRC56
30 lung cancer 28.8 VIM U2AF1 TP53 PTGS2 PTEN PPP2R1A
31 colorectal cancer 28.8 VIM U2AF1 TP53 PTGS2 PTEN POLE
32 breast cancer 28.7 VIM TP53 PTGS2 PTEN PPP2R1A POLE
33 high-grade astrocytoma 10.5 TP53 PTEN
34 esophagus small cell carcinoma 10.5 PIK3CA ERBB2
35 apocrine adenosis of breast 10.4 TP53 ERBB2
36 testicular gonadoblastoma 10.4 VIM KIT
37 hypoganglionosis 10.4 ERBB3 ERBB2
38 glottis squamous cell carcinoma 10.4 PTEN EGFR
39 breast sarcoma 10.4 TP53 KIT ERBB2
40 lung oat cell carcinoma 10.4 TP53 PTEN PIK3CA
41 breast juvenile papillomatosis 10.4 PTEN PIK3CA ERBB2
42 vulvar sebaceous carcinoma 10.4 TP53 KRT8
43 esophagus verrucous carcinoma 10.4 TP53 PIK3CA EGFR
44 lymphoepithelioma-like thymic carcinoma 10.4 KRT8 KIT
45 verrucous carcinoma 10.4 TP53 PIK3CA EGFR
46 familial ovarian cancer 10.4 TP53 POLE
47 barrett's adenocarcinoma 10.4 TP53 PTGS2 ERBB2
48 good syndrome 10.4 TP53 ERBB2 EGFR
49 idh-wildtype glioblastoma 10.4 TP53 PTEN EGFR
50 uterine sarcoma 10.4

Graphical network of the top 20 diseases related to Uterine Carcinosarcoma:



Diseases related to Uterine Carcinosarcoma

Symptoms & Phenotypes for Uterine Carcinosarcoma

UMLS symptoms related to Uterine Carcinosarcoma:


pelvic pain

GenomeRNAi Phenotypes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

25 (show top 50) (show all 64)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.85 POLE
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.85 PIK3R1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.85 VIM
4 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.85 ERBB3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.85 U2AF1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.85 EGFR FBXW7
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.85 FBXW7
8 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.85 POLE
9 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.85 U2AF1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.85 PTEN
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.85 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-153 10.85 U2AF1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.85 KIT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.85 PTEN
15 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.85 ERBB2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.85 ERBB2 POLE PTEN
17 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.85 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.85 PIK3R1 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.85 FBXW7
20 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.85 VIM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.85 HRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.85 POLE PIK3R1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.85 ERBB2 POLE
24 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.85 EGFR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.85 U2AF1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.85 PTEN EGFR PIK3R1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.85 HRAS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.85 KIT
29 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.85 ERBB2 POLE
30 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.85 PIK3R1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.85 PTEN
32 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.85 EGFR PIK3R1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.85 FBXW7
34 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.85 ERBB2 ERBB3
35 Increased shRNA abundance (Z-score > 2) GR00366-A-61 10.85 KIT
36 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.85 ERBB2 POLE PTEN VIM
37 Increased shRNA abundance (Z-score > 2) GR00366-A-66 10.85 PTEN
38 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.85 H2AC18
39 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.85 HRAS
40 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.85 ERBB2 POLE EGFR ERBB3 KIT U2AF1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.85 ERBB2 HRAS POLE PTEN
42 Increased shRNA abundance (Z-score > 2) GR00366-A-89 10.85 U2AF1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.85 KIT
44 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.85 POLE EGFR U2AF1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.85 PTEN
46 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.85 H2AC18 KIT
47 Decreased viability GR00055-A-1 10.41 EGFR HRAS PIK3CA
48 Decreased viability GR00055-A-2 10.41 EGFR HRAS PIK3CA
49 Decreased viability GR00221-A-1 10.41 EGFR HRAS KIT PIK3CA PIK3R1
50 Decreased viability GR00221-A-2 10.41 HRAS PIK3CA

MGI Mouse Phenotypes related to Uterine Carcinosarcoma:

45 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.48 EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
2 homeostasis/metabolism MP:0005376 10.48 EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
3 nervous system MP:0003631 10.43 EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
4 normal MP:0002873 10.41 EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
5 growth/size/body region MP:0005378 10.41 EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
6 cardiovascular system MP:0005385 10.39 CHD4 EGFR ERBB2 ERBB3 FBXW7 FGFR2
7 muscle MP:0005369 10.35 EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
8 endocrine/exocrine gland MP:0005379 10.34 CHD4 EGFR ERBB2 ERBB3 FBXW7 FGFR2
9 embryo MP:0005380 10.32 CHD4 EGFR ERBB2 ERBB3 FBXW7 FGFR2
10 immune system MP:0005387 10.31 CHD4 EGFR ERBB3 FBXW7 FGFR2 KIT
11 cellular MP:0005384 10.29 CHD4 EGFR ERBB2 ERBB3 FBXW7 FGFR2
12 behavior/neurological MP:0005386 10.28 CHD4 ERBB2 ERBB3 FGFR2 HRAS KIT
13 digestive/alimentary MP:0005381 10.27 EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
14 liver/biliary system MP:0005370 10.22 EGFR FBXW7 FGFR2 KIT KRT8 PIK3R1
15 no phenotypic analysis MP:0003012 10.19 CHD4 EGFR FGFR2 HRAS KIT PIK3CA
16 pigmentation MP:0001186 10.16 EGFR ERBB3 FGFR2 KIT PTEN TP53
17 respiratory system MP:0005388 10.15 EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
18 adipose tissue MP:0005375 10.1 EGFR FGFR2 PIK3CA PIK3R1 PTEN PTGS2
19 reproductive system MP:0005389 10.1 EGFR ERBB2 FBXW7 FGFR2 KIT KRT8
20 vision/eye MP:0005391 10 EGFR FBXW7 FGFR2 KIT PIK3CA PIK3R1
21 hematopoietic system MP:0005397 10 CHD4 EGFR ERBB2 FBXW7 FGFR2 KIT
22 mortality/aging MP:0010768 9.93 CHD4 EGFR ERBB2 ERBB3 FBXW7 FGFR2
23 integument MP:0010771 9.5 EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS

Drugs & Therapeutics for Uterine Carcinosarcoma

Drugs for Uterine Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904
2
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
3
Pertuzumab Approved Phase 2, Phase 3 380610-27-5
4
Trastuzumab Approved, Investigational Phase 2, Phase 3 180288-69-1
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
8
Palifosfamide Investigational Phase 3 31645-39-3 100427
9 Antineoplastic Agents, Immunological Phase 2, Phase 3
10 Albumin-Bound Paclitaxel Phase 2, Phase 3
11 Antimitotic Agents Phase 2, Phase 3
12 Tubulin Modulators Phase 2, Phase 3
13 Alkylating Agents Phase 3
14 Antineoplastic Agents, Alkylating Phase 3
15
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
16
Aflibercept Approved Phase 2 862111-32-8 124490314
17
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
18
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
19
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
20
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
21
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
22
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
23
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
24
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
25
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
26
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
27
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
28
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
29
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
30
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
31
Iniparib Investigational Phase 2 160003-66-7 9796068
32
Saracatinib Investigational Phase 2 379231-04-6 10302451
33
MK-1775 Investigational Phase 2 955365-80-7 24856436
34
Spartalizumab Investigational Phase 2 1935694-88-4
35 Liver Extracts Phase 2
36 Antimetabolites Phase 2
37
Imatinib Mesylate Phase 2 220127-57-1
38 Epothilones Phase 2
39 Epothilone B Phase 2 4456137
40 Protein Kinase Inhibitors Phase 2
41 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
42 Angiogenesis Inhibitors Phase 2
43 Immune Checkpoint Inhibitors Phase 2
44 Antiprotozoal Agents Phase 2
45 Antiparasitic Agents Phase 2
46 Antimalarials Phase 2
47 Hypoglycemic Agents Phase 2
48 Immunoglobulins, Intravenous Phase 2
49 Immunoglobulins Phase 2
50 Immunoglobulin G Phase 2

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma Recruiting NCT05256225 Phase 2, Phase 3 Carboplatin;Hyaluronidase-zzxf/Pertuzumab/Trastuzumab;Paclitaxel;Trastuzumab/Hyaluronidase-oysk
2 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
3 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Active, not recruiting NCT03422198 Phase 3
4 A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
5 A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00112489 Phase 2 carboplatin;paclitaxel
6 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
7 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
8 A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas Completed NCT00390234 Phase 2 ziv-aflibercept
9 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
10 A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma Completed NCT00238121 Phase 2 sorafenib tosylate
11 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
12 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
13 A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
14 A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00075400 Phase 2 imatinib mesylate
15 A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
16 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01168232 Phase 2 Ixabepilone
17 A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas Recruiting NCT05147558 Phase 2 Pembrolizumab;Lenvatinib
18 A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Recruiting NCT03668340 Phase 2 AZD1775
19 An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma Active, not recruiting NCT03694262 Phase 2 Rucaparib;Bevacizumab;Atezolizumab
20 Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff Active, not recruiting NCT04802876 Phase 2 Spartalizumab
21 A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT01935934 Phase 2 Cabozantinib S-malate
22 A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer Active, not recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
23 The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma Not yet recruiting NCT05619913 Phase 2 Eribulin Mesylate;Pembrolizumab
24 Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
25 A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients With Advanced Solid Tumors Recruiting NCT05229601 Phase 1 HFB301001
26 Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex) Recruiting NCT02020707 Phase 1 Nab-paclitaxel
27 Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer Recruiting NCT03120624 Phase 1 Ruxolitinib;Ruxolitinib Phosphate;Technetium Tc-99m Sodium Pertechnetate
28 Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT03552471 Phase 1 Rucaparib Camsylate
29 A Pilot Investigation to Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers Recruiting NCT05049538
30 A Pilot Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Carcinosarcoma Terminated NCT01367301 paclitaxel;carboplatin
31 Pilot Study of Tislelizumab (BGB-A317) in Recurrent Mismatch Repair Deficient Endometrial Cancer and the Effect on the Tumor Microenvironment Terminated NCT04906382 Early Phase 1 Carboplatin;Paclitaxel
32 Web-Based Coping and Communication Skills Intervention for Women Who Are Newly Diagnosed With Gynecological Cancer: A Pilot Study Withdrawn NCT03902379

Search NIH Clinical Center for Uterine Carcinosarcoma

Genetic Tests for Uterine Carcinosarcoma

Anatomical Context for Uterine Carcinosarcoma

Organs/tissues related to Uterine Carcinosarcoma:

MalaCards : Uterus, Ovary, Breast, Endothelial, Liver, Lymph Node, Adrenal Gland

Publications for Uterine Carcinosarcoma

Articles related to Uterine Carcinosarcoma:

(show top 50) (show all 491)
# Title Authors PMID Year
1
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
2
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. 53 62
20189232 2010
3
COX-2 expression in uterine carcinosarcoma. 53 62
19900134 2010
4
Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. 53 62
17175012 2007
5
Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment? 53 62
16445668 2006
6
HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. 53 62
15901136 2005
7
Cyclooxygenase-2 expression in uterine leiomyosarcomas. 53 62
15700850 2004
8
ERBB-2 gene overexpression and amplification in uterine sarcomas. 53 62
15581967 2004
9
Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. 53 62
14611676 2003
10
Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. 53 62
9311600 1997
11
Improved survival with combination chemotherapy and external beam radiation therapy in uterine carcinosarcoma. 62
36343971 2022
12
Feline uterine carcinosarcoma infiltrated with osteoclast-like giant cells. 62
36261364 2022
13
Radical abdomino-pelvic surgery in the management of uterine carcinosarcoma with concomitant para-aortic lymphadenopathy metastasising from anal carcinoma. 62
36450419 2022
14
Identification of drug targets and prognosis projection for uterine carcinosarcoma based on alternative splicing events. 62
36470146 2022
15
Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types. 62
36255654 2022
16
Inter-component immunohistochemical assessment of proliferative markers in uterine carcinosarcoma. 62
36238851 2022
17
Incidence and survival rates of primary uterine carcinosarcoma in Korea: a National Cancer Registry study. 62
36366811 2022
18
Management and Prognosis of Patients with Recurrent or Persistent/Progressive Uterine Carcinosarcoma. 62
36290878 2022
19
HER2 amplification in Uterine carcinosarcoma after tamoxifen therapy: a case report. 62
36149352 2022
20
Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival. 62
34797919 2022
21
cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma. 62
36178283 2022
22
Characterizing the extracellular matrix transcriptome of cervical, endometrial, and uterine cancers. 62
35898192 2022
23
Clostridium and Bacteroides bacteremia as initial presentation of uterine carcinosarcoma. 62
35866177 2022
24
Is minimally invasive surgery for clinical stage I uterine carcinosarcoma safe? 62
34716874 2022
25
Prognostic value of the TCGA molecular classification in uterine carcinosarcoma. 62
34536971 2022
26
The role of multimodal adjuvant therapy for FIGO I-II carcinosarcoma of the uterus: a systematic review. 62
35533817 2022
27
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor. 62
35599167 2022
28
Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report. 62
35586703 2022
29
Evaluation of chemotherapy and radiotherapy in the adjuvant management of uterine carcinosarcoma: a population-based analysis. 62
35708782 2022
30
Role of Nucleolin in Endometrial Precancerous Hyperplasia and Carcinogenesis: Ex Vivo and In Silico Study. 62
35682908 2022
31
Radiotherapy-induced uterine cacinosarcoma: A case report and review of the literature. 62
35397302 2022
32
Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma. 62
35232588 2022
33
Abandon ifosfamide-based regimen and use paclitaxel-carboplatin regimen for the treatment of uterine carcinosarcoma. 62
35385437 2022
34
Uterine carcinosarcoma associated with a germline nibrin (NBN) mutation. 62
35434237 2022
35
Increasing incidence of uterine carcinosarcoma: A United States Cancer Statistics study. 62
35169605 2022
36
HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology. 62
35125452 2022
37
Synchronous uterine and bladder cancers detected in urine and vaginal samples by cytology. 62
34783454 2022
38
Evaluation of Saccharomyces cerevisiae-like 1 (SEC14L1) in Gynecologic Malignancies Shows Overexpression in Endometrial Serous Carcinoma. 62
35283446 2022
39
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. 62
35007153 2022
40
Paclitaxel and Carboplatin for Uterine Carcinosarcoma: A Path to Inclusion. 62
35044808 2022
41
Response to anti-DKK1 therapy in uterine carcinosarcoma: A case report. 62
35531363 2022
42
Patterns of adjuvant treatment and survival outcomes in stage I uterine carcinosarcoma. 62
35111895 2022
43
Comparing paclitaxel-platinum with ifosfamide-platinum as the front-line chemotherapy for patients with advanced-stage uterine carcinosarcoma. 62
34698689 2022
44
Retrospective Analysis of Patients with Gynaecological Uterine Sarcomas in a Tertiary Hospital. 62
35207710 2022
45
Non-islet cell tumor hypoglycemia in a patient with uterine carcinosarcoma. 62
35005156 2022
46
How and where to expect endosalpingiosis intraoperatively. 62
34986982 2022
47
Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis. 62
35663977 2022
48
Exercise-induced IL-15 acted as a positive prognostic implication and tumor-suppressed role in pan-cancer. 62
36467072 2022
49
A transcriptome-Based Deep Neural Network Classifier for Identifying the Site of Origin in Mucinous Cancer. 62
36408331 2022
50
Clinicopathological Features Associated with Microsatellite Instability/Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Quantitative Systematic Review. 62
35231921 2022

Variations for Uterine Carcinosarcoma

ClinVar genetic disease variations for Uterine Carcinosarcoma:

5 (show top 50) (show all 174)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PIK3CA NM_006218.4(PIK3CA):c.316G>C (p.Gly106Arg) SNV Likely Pathogenic
376480 rs1057519931 GRCh37: 3:178916929-178916929
GRCh38: 3:179199141-179199141
2 FBXW7 NM_001349798.2(FBXW7):c.1973G>A (p.Arg658Gln) SNV Likely Pathogenic
376427 rs759610249 GRCh37: 4:153244184-153244184
GRCh38: 4:152323032-152323032
3 PPP2R1A NM_014225.6(PPP2R1A):c.536C>G (p.Pro179Arg) SNV Likely Pathogenic
376504 rs786205228 GRCh37: 19:52715971-52715971
GRCh38: 19:52212718-52212718
4 POLE NM_006231.4(POLE):c.856C>T (p.Pro286Ser) SNV Likely Pathogenic
376501 rs1057519944 GRCh37: 12:133253185-133253185
GRCh38: 12:132676599-132676599
5 POLE NM_006231.4(POLE):c.857C>A (p.Pro286His) SNV Likely Pathogenic
376502 rs1057519943 GRCh37: 12:133253184-133253184
GRCh38: 12:132676598-132676598
6 PIK3R1 NM_181523.3(PIK3R1):c.1126G>C (p.Gly376Arg) SNV Likely Pathogenic
376065 rs1057519757 GRCh37: 5:67589138-67589138
GRCh38: 5:68293310-68293310
7 PPP2R1A NM_014225.6(PPP2R1A):c.536C>T (p.Pro179Leu) SNV Likely Pathogenic
190313 rs786205228 GRCh37: 19:52715971-52715971
GRCh38: 19:52212718-52212718
8 PIK3CA NM_006218.4(PIK3CA):c.317G>T (p.Gly106Val) SNV Likely Pathogenic
376479 rs1057519930 GRCh37: 3:178916930-178916930
GRCh38: 3:179199142-179199142
9 ERBB3 NM_001982.4(ERBB3):c.889G>A (p.Asp297Asn) SNV Likely Pathogenic
376409 rs1057519891 GRCh37: 12:56482341-56482341
GRCh38: 12:56088557-56088557
10 FBXW7 NM_001349798.2(FBXW7):c.1513C>A (p.Arg505Ser) SNV Likely Pathogenic
376426 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
11 PPP2R1A NM_014225.6(PPP2R1A):c.548G>A (p.Arg183Gln) SNV Likely Pathogenic
376506 rs1057519947 GRCh37: 19:52715983-52715983
GRCh38: 19:52212730-52212730
12 FBXW7 NM_001349798.2(FBXW7):c.1513C>G (p.Arg505Gly) SNV Likely Pathogenic
376423 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
13 FBXW7 NM_001349798.2(FBXW7):c.1435C>G (p.Arg479Gly) SNV Likely Pathogenic
376422 rs747241612 GRCh37: 4:153247367-153247367
GRCh38: 4:152326215-152326215
14 ERBB2 NM_004448.4(ERBB2):c.2524G>A (p.Val842Ile) SNV Likely Pathogenic
375994 rs1057519738 GRCh37: 17:37881332-37881332
GRCh38: 17:39725079-39725079
15 ERBB3 NM_001982.4(ERBB3):c.310G>A (p.Val104Met) SNV Likely Pathogenic
376410 rs1057519893 GRCh37: 12:56478854-56478854
GRCh38: 12:56085070-56085070
16 PPP2R1A NM_014225.6(PPP2R1A):c.547C>T (p.Arg183Trp) SNV Likely Pathogenic
376505 rs1057519946 GRCh37: 19:52715982-52715982
GRCh38: 19:52212729-52212729
17 PPP2R1A NM_014225.6(PPP2R1A):c.547C>G (p.Arg183Gly) SNV Likely Pathogenic
376507 rs1057519946 GRCh37: 19:52715982-52715982
GRCh38: 19:52212729-52212729
18 PIK3CA NM_006218.4(PIK3CA):c.1034A>C (p.Asn345Thr) SNV Likely Pathogenic
376489 rs1057519938 GRCh37: 3:178921552-178921552
GRCh38: 3:179203764-179203764
19 FBXW7 NM_001349798.2(FBXW7):c.1514G>T (p.Arg505Leu) SNV Likely Pathogenic
376424 rs1057519896 GRCh37: 4:153247288-153247288
GRCh38: 4:152326136-152326136
20 FBXW7 NM_001349798.2(FBXW7):c.1513C>T (p.Arg505Cys) SNV Likely Pathogenic
69961 rs149680468 GRCh37: 4:153247289-153247289
GRCh38: 4:152326137-152326137
21 FBXW7 NM_001349798.2(FBXW7):c.1436G>C (p.Arg479Pro) SNV Likely Pathogenic
376420 rs866987936 GRCh37: 4:153247366-153247366
GRCh38: 4:152326214-152326214
22 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely Pathogenic
13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
23 PIK3CA NM_006218.4(PIK3CA):c.1034A>T (p.Asn345Ile) SNV Likely Pathogenic
376488 rs1057519938 GRCh37: 3:178921552-178921552
GRCh38: 3:179203764-179203764
24 PIK3CA NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly) SNV Likely Pathogenic
13656 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
25 U2AF1 NM_006758.3(U2AF1):c.101C>A (p.Ser34Tyr) SNV Likely Pathogenic
376026 rs371769427 GRCh37: 21:44524456-44524456
GRCh38: 21:43104346-43104346
26 ERBB3 NM_001982.4(ERBB3):c.310G>T (p.Val104Leu) SNV Likely Pathogenic
376411 rs1057519893 GRCh37: 12:56478854-56478854
GRCh38: 12:56085070-56085070
27 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln) SNV Likely Pathogenic
375896 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
28 U2AF1 NM_006758.3(U2AF1):c.101C>T (p.Ser34Phe) SNV Likely Pathogenic
376025 rs371769427 GRCh37: 21:44524456-44524456
GRCh38: 21:43104346-43104346
29 FBXW7 NM_001349798.2(FBXW7):c.1514G>A (p.Arg505His) SNV Likely Pathogenic
376425 rs1057519896 GRCh37: 4:153247288-153247288
GRCh38: 4:152326136-152326136
30 ERBB3 NM_001982.4(ERBB3):c.890A>T (p.Asp297Val) SNV Likely Pathogenic
376408 rs1057519892 GRCh37: 12:56482342-56482342
GRCh38: 12:56088558-56088558
31 FBXW7 NM_001349798.2(FBXW7):c.1436G>T (p.Arg479Leu) SNV Likely Pathogenic
376421 rs866987936 GRCh37: 4:153247366-153247366
GRCh38: 4:152326214-152326214
32 PIK3CA NM_006218.4(PIK3CA):c.263G>A (p.Arg88Gln) SNV Likely Pathogenic
376049 rs121913287 GRCh37: 3:178916876-178916876
GRCh38: 3:179199088-179199088
33 PIK3CA NM_006218.4(PIK3CA):c.1033A>C (p.Asn345His) SNV Likely Pathogenic
376490 rs1057519939 GRCh37: 3:178921551-178921551
GRCh38: 3:179203763-179203763
34 ERBB3 NM_001982.4(ERBB3):c.889G>T (p.Asp297Tyr) SNV Likely Pathogenic
376407 rs1057519891 GRCh37: 12:56482341-56482341
GRCh38: 12:56088557-56088557
35 FBXW7 NM_001349798.2(FBXW7):c.1436G>A (p.Arg479Gln) SNV Likely Pathogenic
376419 rs866987936 GRCh37: 4:153247366-153247366
GRCh38: 4:152326214-152326214
36 FBXW7 NM_001349798.2(FBXW7):c.1394G>C (p.Arg465Pro) SNV Likely Pathogenic
376416 rs1057519895 GRCh37: 4:153249384-153249384
GRCh38: 4:152328232-152328232
37 FBXW7 NM_001349798.2(FBXW7):c.1394G>T (p.Arg465Leu) SNV Likely Pathogenic
376417 rs1057519895 GRCh37: 4:153249384-153249384
GRCh38: 4:152328232-152328232
38 PIK3CA NM_006218.4(PIK3CA):c.1637A>T (p.Gln546Leu) SNV Likely Pathogenic
375899 rs397517201 GRCh37: 3:178936095-178936095
GRCh38: 3:179218307-179218307
39 PIK3CA NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp) SNV Likely Pathogenic
217293 rs121913275 GRCh37: 3:178936093-178936093
GRCh38: 3:179218305-179218305
40 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg) SNV Likely Pathogenic
45466 rs397517201 GRCh37: 3:178936095-178936095
GRCh38: 3:179218307-179218307
41 PIK3CA NM_006218.4(PIK3CA):c.1636C>G (p.Gln546Glu) SNV Likely Pathogenic
13654 rs121913286 GRCh37: 3:178936094-178936094
GRCh38: 3:179218306-179218306
42 FBXW7 NM_001349798.2(FBXW7):c.1394G>A (p.Arg465His) SNV Likely Pathogenic
376415 rs1057519895 GRCh37: 4:153249384-153249384
GRCh38: 4:152328232-152328232
43 FBXW7 NM_001349798.2(FBXW7):c.1393C>T (p.Arg465Cys) SNV Likely Pathogenic
376414 rs867384286 GRCh37: 4:153249385-153249385
GRCh38: 4:152328233-152328233
44 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu) SNV Likely Pathogenic
13653 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
45 PIK3CA NM_006218.4(PIK3CA):c.1637A>C (p.Gln546Pro) SNV Likely Pathogenic
375898 rs397517201 GRCh37: 3:178936095-178936095
GRCh38: 3:179218307-179218307
46 PIK3CA NM_006218.4(PIK3CA):c.1636C>A (p.Gln546Lys) SNV Likely Pathogenic
13657 rs121913286 GRCh37: 3:178936094-178936094
GRCh38: 3:179218306-179218306
47 FBXW7 NM_001349798.2(FBXW7):c.1393C>G (p.Arg465Gly) SNV Likely Pathogenic
376418 rs867384286 GRCh37: 4:153249385-153249385
GRCh38: 4:152328233-152328233
48 PIK3CA NM_006218.4(PIK3CA):c.1638G>T (p.Gln546His) SNV Likely Pathogenic
376491 rs1057519940 GRCh37: 3:178936096-178936096
GRCh38: 3:179218308-179218308
49 PIK3CA NM_006218.4(PIK3CA):c.3141T>G (p.His1047Gln) SNV Likely Pathogenic
376481 rs1057519932 GRCh37: 3:178952086-178952086
GRCh38: 3:179234298-179234298
50 PIK3CA NM_006218.4(PIK3CA):c.1035T>A (p.Asn345Lys) SNV Likely Pathogenic
376050 rs121913284 GRCh37: 3:178921553-178921553
GRCh38: 3:179203765-179203765

Expression for Uterine Carcinosarcoma

Search GEO for disease gene expression data for Uterine Carcinosarcoma.

Pathways for Uterine Carcinosarcoma

Pathways related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 VIM TP53 PTGS2 PTEN PPP2R1A PIK3R1
2
Show member pathways
13.84 CHD4 EGFR ERBB2 ERBB3 FBXW7 FGFR2
3
Show member pathways
13.8 EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
4
Show member pathways
13.73 TP53 PTGS2 PPP2R1A PIK3R1 KIT HRAS
5 13.72 VIM TP53 PTEN PPP2R1A PIK3R1 PIK3CA
6
Show member pathways
13.64 TP53 PPP2R1A PIK3R1 PIK3CA KIT HRAS
7
Show member pathways
13.57 TP53 PTEN PIK3R1 PIK3CA HRAS FGFR2
8
Show member pathways
13.52 TP53 PTEN PPP2R1A PIK3R1 KIT HRAS
9
Show member pathways
13.47 EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
10
Show member pathways
13.42 EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
11
Show member pathways
13.41 VIM TP53 PTGS2 PPP2R1A PIK3R1 PIK3CA
12
Show member pathways
13.39 PTEN PIK3R1 KIT HRAS FGFR2 ERBB2
13
Show member pathways
13.39 VIM PPP2R1A PIK3R1 KIT HRAS FGFR2
14
Show member pathways
13.17 TP53 PTEN PIK3R1 KIT HRAS FGFR2
15
Show member pathways
13.16 EGFR FGFR2 HRAS KIT PIK3R1 PPP2R1A
16
Show member pathways
13.06 EGFR FGFR2 HRAS KIT PIK3CA PIK3R1
17
Show member pathways
13.04 CHD4 EGFR ERBB2 ERBB3 FGFR2 KIT
18
Show member pathways
13.03 KIT FGFR2 ERBB3 ERBB2 EGFR
19
Show member pathways
13.01 TP53 PTEN PIK3R1 PIK3CA HRAS EGFR
20
Show member pathways
12.99 EGFR ERBB2 ERBB3 FGFR2 HRAS PIK3CA
21
Show member pathways
12.93 PIK3R1 PIK3CA KIT HRAS EGFR
22
Show member pathways
12.83 EGFR HRAS PIK3CA PIK3R1 PTEN
23 12.83 TP53 PTEN PIK3CA KIT HRAS FGFR2
24 12.79 PPP2R1A PIK3R1 PIK3CA KIT HRAS FGFR2
25
Show member pathways
12.76 TP53 PPP2R1A PIK3R1 HRAS EGFR
26
Show member pathways
12.76 TP53 PPP2R1A PIK3R1 PIK3CA KIT HRAS
27
Show member pathways
12.72 EGFR ERBB2 HRAS PIK3CA PIK3R1 TP53
28
Show member pathways
12.71 EGFR ERBB2 ERBB3 FGFR2 KIT PIK3CA
29
Show member pathways
12.69 PPP2R1A PIK3R1 PIK3CA HRAS FGFR2
30
Show member pathways
12.66 PPP2R1A PIK3R1 PIK3CA HRAS CHD4
31
Show member pathways
12.62 EGFR ERBB2 ERBB3 HRAS PIK3CA PIK3R1
32
Show member pathways
12.56 TP53 PTGS2 PTEN PIK3R1 PIK3CA HRAS
33
Show member pathways
12.53 EGFR ERBB2 ERBB3 FGFR2 HRAS PIK3CA
34
Show member pathways
12.52 EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
35
Show member pathways
12.5 PIK3R1 PIK3CA HRAS FGFR2
36
Show member pathways
12.49 PIK3R1 PIK3CA HRAS EGFR
37
Show member pathways
12.48 EGFR FGFR2 HRAS PIK3R1
38 12.48 TP53 HRAS FGFR2 EGFR
39
Show member pathways
12.48 PTGS2 PIK3R1 PIK3CA HRAS
40
Show member pathways
12.44 TP53 PTGS2 PIK3R1 PIK3CA HRAS
41 12.43 PTEN PIK3R1 PIK3CA HRAS ERBB2 EGFR
42
Show member pathways
12.42 PTEN PIK3R1 PIK3CA HRAS
43
Show member pathways
12.42 EGFR ERBB2 ERBB3 HRAS PIK3CA PIK3R1
44
Show member pathways
12.41 PTEN PIK3R1 PIK3CA HRAS
45
Show member pathways
12.4 PTEN PPP2R1A PIK3R1 PIK3CA EGFR
46
Show member pathways
12.39 PPP2R1A PIK3R1 PIK3CA HRAS FGFR2
47
Show member pathways
12.38 TP53 PTEN PIK3R1 PIK3CA HRAS
48 12.38 PIK3R1 PIK3CA KIT HRAS FGFR2 EGFR
49
Show member pathways
12.37 PIK3R1 PIK3CA HRAS ERBB3 ERBB2 EGFR
50
Show member pathways
12.35 PIK3R1 PIK3CA HRAS EGFR

GO Terms for Uterine Carcinosarcoma

Cellular components related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.96 KIT FGFR2 ERBB3 ERBB2 EGFR
2 ERBB3:ERBB2 complex GO:0038143 9.46 ERBB3 ERBB2
3 plasma membrane region GO:0098590 9.13 ERBB3 ERBB2 EGFR
4 obsolete spanning component of plasma membrane GO:0044214 8.8 ERBB3 ERBB2 EGFR

Biological processes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.22 PTEN HRAS FGFR2 FBXW7 EGFR
2 negative regulation of apoptotic process GO:0043066 10.22 TP53 PTGS2 PTEN PIK3R1 ERBB3 ERBB2
3 positive regulation of cell population proliferation GO:0008284 10.17 PTGS2 PTEN KIT HRAS FGFR2 ERBB3
4 positive regulation of MAP kinase activity GO:0043406 10.1 EGFR ERBB2 HRAS KIT
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 10.1 EGFR ERBB2 ERBB3 FGFR2 KIT
6 peptidyl-tyrosine phosphorylation GO:0018108 10.09 KIT FGFR2 ERBB3 ERBB2 EGFR
7 positive regulation of epithelial cell proliferation GO:0050679 10.06 HRAS FGFR2 ERBB2 EGFR
8 embryonic organ development GO:0048568 10.02 TP53 POLE FGFR2
9 regulation of ERK1 and ERK2 cascade GO:0070372 9.99 FGFR2 ERBB2 EGFR
10 phosphorylation GO:0016310 9.97 PIK3R1 PIK3CA KIT FGFR2 ERBB3 ERBB2
11 positive regulation of kinase activity GO:0033674 9.96 EGFR ERBB2 ERBB3 FGFR2 KIT
12 ERBB2-ERBB3 signaling pathway GO:0038133 9.84 ERBB3 ERBB2
13 phosphatidylinositol 3-kinase signaling GO:0014065 9.65 PTEN PIK3R1 PIK3CA ERBB3 ERBB2
14 multicellular organism development GO:0007275 9.55 KIT FGFR2 ERBB3 ERBB2 EGFR
15 regulation of cell population proliferation GO:0042127 9.32 TP53 PTGS2 KIT HRAS ERBB3 ERBB2

Molecular functions related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 10.15 TP53 PPP2R1A PIK3R1 H2AC18 ERBB3 ERBB2
2 nucleotide binding GO:0000166 10.02 POLE PIK3CA KIT HRAS FGFR2 ERBB3
3 protein phosphatase binding GO:0019903 10.01 TP53 PIK3R1 ERBB2 EGFR
4 protein tyrosine kinase activity GO:0004713 9.96 EGFR ERBB2 ERBB3 FGFR2 KIT
5 kinase activity GO:0016301 9.76 PIK3R1 PIK3CA KIT FGFR2 ERBB3 ERBB2
6 ErbB-3 class receptor binding GO:0043125 9.43 PIK3R1 ERBB3 ERBB2
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.28 KIT FGFR2 ERBB3 ERBB2 EGFR

Sources for Uterine Carcinosarcoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....